Johnson & Johnson (NYSE:JNJ – Get Rating) had its target price reduced by research analysts at SVB Leerink from $194.00 to $186.00 in a report released on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s target price points to a potential upside of 9.7 from the company’s current price.

→ Is This The End of Capitalism? (From Porter & Company)

JNJ has been the subject of several other research reports. Barclays started coverage on Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target for the company. Raymond James cut their price target on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. StockNews.com began coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating for the company. Morgan Stanley dropped their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 6th. Finally, Citigroup upped their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has ass igned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $169.53 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The stock has a 50 day moving average of $176.15 and a two-hundred day moving average of $171.37. The stock has a market cap of $443.23 billion, a P/E ratio of 23.61, a P/E/G ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson turned had a return on equity of 35.37% and a net margin of 19.95%. The company had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter in the previous year, the business earned $2.60 earnings. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, The chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Joseph Jold. 14,781 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 values ​​of the company shares’ at $6,431,835.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. here. Over the last 90 days, insiders have sold 277,886 shares of company stock valued at $48,550,549. Insiders own 0.35% of the company’s stock.

Institutional Trading of Johnson & Johnson

A number of large investors have recently made changes to their positions in the stock. Morton Brown Family Wealth LLC lifted its position in Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock w $32,000 after buying an additional 78 shares during the period. Glassy Mountain Advisors Inc. purchased a new position in Johnson & Johnson during the fourth quarter worth about $35,000. Goodman Advisory Group LLC purchased a new position in Johnson & Johnson during the quer about the art $39,000. Retirement Financial Solutions LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $40,000. Finally, Cardinal Capital Management Inc. lifted its position in Johnson & Johnson by 333.3% during the second Manal quarter Capterapi. owns 260 shares of the company’s stock worth $46,000 after buying an additional 200 shares during the period. Institutional investor s and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story [email protected].

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here